NGNE Fundamental Analysis - NEUROGENE INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NGNE. NGNE was compared to 549 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

NGNE had negative earnings in the past year.

NGNE had a negative operating cash flow in the past year.

In the past 5 years NGNE always reported negative net income.

In the past 5 years NGNE always reported negative operating cash flow.

1.2 Ratios

NGNE's Return On Assets of -22.38% is fine compared to the rest of the industry. NGNE outperforms 76.50% of its industry peers.

NGNE's Return On Equity of -24.21% is amongst the best of the industry. NGNE outperforms 81.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-22.38%
ROE	-24.21%
ROIC	N/A

ROA(3y)-29.45%

ROA(5y)-28.26%

ROE(3y)-34.92%

ROE(5y)-32.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.

NGNE has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, NGNE has more shares outstanding

Compared to 1 year ago, NGNE has an improved debt to assets ratio.

2.2 Solvency

NGNE has an Altman-Z score of 5.83. This indicates that NGNE is financially healthy and has little risk of bankruptcy at the moment.

NGNE's Altman-Z score of 5.83 is fine compared to the rest of the industry. NGNE outperforms 79.23% of its industry peers.

NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

The Debt to Equity ratio of NGNE (0.00) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	5.83

ROIC/WACCN/A

WACC9.8%

2.3 Liquidity

A Current Ratio of 20.84 indicates that NGNE has no problem at all paying its short term obligations.

With an excellent Current ratio value of 20.84, NGNE belongs to the best of the industry, outperforming 95.08% of the companies in the same industry.

NGNE has a Quick Ratio of 20.84. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.

NGNE has a better Quick ratio (20.84) than 95.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	20.84
Quick Ratio	20.84

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NGNE shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.48%.

EPS 1Y (TTM)-7.48%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%3.67%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -10.73% on average over the next years. This is quite bad

The Revenue is expected to grow by 132.08% on average over the next years. This is a very strong growth

EPS Next Y-14.45%

EPS Next 2Y-10.63%

EPS Next 3Y-10.73%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y132.08%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NGNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NGNE's earnings are expected to decrease with -10.73% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.63%

EPS Next 3Y-10.73%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NGNE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (8/20/2025, 8:13:57 PM)

After market: 19.61 0 (0%)

19.61

-0.1 (-0.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-11 2025-08-11/amc

Earnings (Next)11-17 2025-11-17/bmo

Inst Owners115.65%

Inst Owner Change-9.8%

Ins Owners9.23%

Ins Owner Change3.47%

Market Cap279.83M

Analysts86.15

Price Target48.76 (148.65%)

Short Float %20.01%

Short Ratio15.14

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)9.3%

Min EPS beat(2)4.5%

Max EPS beat(2)14.11%

EPS beat(4)3

Avg EPS beat(4)7.61%

Min EPS beat(4)-1.77%

Max EPS beat(4)14.11%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)12.21%

PT rev (3m)7.66%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)-4.38%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	302.52
P/FCF	N/A
P/OCF	N/A
P/B	0.9
P/tB	0.9
EV/EBITDA	N/A

EPS(TTM)-4.31

EYN/A

EPS(NY)-5.23

Fwd EYN/A

FCF(TTM)-5

FCFYN/A

OCF(TTM)-4.95

OCFYN/A

SpS0.06

BVpS21.75

TBVpS21.75

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-22.38%
ROE	-24.21%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-29.45%

ROA(5y)-28.26%

ROE(3y)-34.92%

ROE(5y)-32.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	25.29%
Cap/Sales	87.35%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	20.84
Quick Ratio	20.84
Altman-Z	5.83

F-Score5

WACC9.8%

ROIC/WACCN/A

Cap/Depr(3y)35.41%

Cap/Depr(5y)127.75%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-7.48%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%3.67%

EPS Next Y-14.45%

EPS Next 2Y-10.63%

EPS Next 3Y-10.73%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y132.08%

EBIT growth 1Y-58.46%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-38.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-37.3%

OCF growth 3YN/A

OCF growth 5YN/A

NEUROGENE INC (NGNE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens